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Recent evidence has demonstrated that endothelial-to-mesenchymal transition (EndMT) may have a significant role in a number of
diseases. Although EndMT has been previously studied as a critical process in heart development, it is now clear that EndMT can also
occur postnatally in various pathologic settings, including cancer and cardiac fibrosis. During EndMT, resident endothelial cells
delaminate from an organised cell layer and acquire a mesenchymal phenotype characterised by loss of cell–cell junctions, loss of
endothelial markers, gain of mesenchymal markers, and acquisition of invasive and migratory properties. Endothelial-to-mesenchymal
transition -derived cells are believed to function as fibroblasts in damaged tissue, and may therefore have an important role in tissue
remodelling and fibrosis. In tumours, EndMT is an important source of cancer-associated fibroblasts (CAFs), which are known to
facilitate tumour progression in several ways. These new findings suggest that targeting EndMT may be a novel therapeutic strategy,
which is broadly applicable not only to cancer but also to various other disease states.
British Journal of Cancer (2008) 99, 1375–1379. doi:10.1038/sj.bjc.6604662 www.bjcancer.com
Published online 16 September 2008
& 2008 Cancer Research UK
Keywords: endothelial-to-mesenchymal transition; EndMT; cancer-associated fibroblasts; angiogenesis; endothelium; fibrosis
                                           
As an integral component of the circulatory system, the
endothelium can be defined as the single-cell layer of mostly
squamous epithelium that provides the inner cell lining of blood
vessels and lymphatics (Junqueira and Carneiro, 2005). Endothelial
cells can exhibit a wide range of phenotypic variability depending
on local physiologic needs throughout the vascular tree (Chi et al,
2003). Furthermore, in pathologic states, the endothelium can be
affected in a number of ways; perhaps the most remarkable is an
extreme form of endothelial plasticity known as endothelial-to-
mesenchymal transition (EndMT).
During EndMT, resident endothelial cells delaminate from an
organised cell layer and invade the underlying tissue (Figure 1).
This so-called mesenchymal phenotype can be characterised by
loss of cell–cell junctions, acquisition of invasive and migratory
properties, loss of endothelial markers, such as CD31 (also known
as platelet endothelial cell adhesion molecule-1 (PECAM-1)), and
gain of mesenchymal markers, such as fibroblast-specific protein 1
(FSP1; also known as S100A4) or a-smooth muscle actin (aSMA;
Potts and Runyan, 1989; Nakajima et al, 2000; Armstrong and
Bischoff, 2004; Arciniegas et al, 2007; Zeisberg et al, 2007a,b).
Previous studies of EndMT have focused largely on embryonic
development of the heart. However, recent evidence suggests that
EndMT can occur postnatally in a variety of pathologic settings,
including cancer and cardiac fibrosis (Zeisberg et al, 2007a,b).
There is also growing evidence that EndMT may be associated with
select types of endothelium in the body.
With regard to cancer, EndMT accounts for up to 40% of
cancer-associated fibroblasts (CAFs). Cancer-associated fibroblasts
play an important role in tumour progression and can alter the
microenvironment in several ways. In particular, CAFs deposit
various extracellular matrix molecules and secrete paracrine
factors that can directly affect the behaviour of many different
cell types within the tumour. Furthermore, CAFs release poten-
tially oncogenic signals, such as transforming growth factor-b
(TGF-b), and are a principle source of host-derived vascular
endothelial growth factor (VEGF), which promotes angiogenesis
(Kalluri and Zeisberg, 2006). Here, we highlight the recent findings
of EndMT as a source of CAFs, with a discussion of proposed
mechanisms and therapeutic implications.
ENDOTHELIAL-TO-MESENCHYMAL TRANSITION VS
EPITHELIAL-TO-MESENCHYMAL TRANSITION
Endothelial-to-mesenchymal transition is often categorised as a
specialised form of epithelial-to-mesenchymal transition (EMT).
Epithelial-to-mesenchymal transition can occur in many epithelial
cell types and is a critical process in embryogenesis (Thiery and
Sleeman, 2006). In the setting of disease, EMT has been
demonstrated during epithelial injury and can also occur in
individual tumour cells as an important mechanism of invasion
and metastasis (Batlle et al, 2000; Cano et al, 2000; Zavadil and
Bottinger, 2005; Thiery and Sleeman, 2006; Tse and Kalluri, 2007).
Epithelial-to-mesenchymal transition has been extensively
studied and has provided a useful framework for guiding research
on EndMT. Both EMT and EndMT give rise to cells that have a
similar mesenchymal phenotype, and current evidence suggests
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studies are needed to validate this notion, as there exist some key
differences between endothelial cells and other types of epithelial cells.
In particular, endothelial cells express distinct cell–cell junctional
proteins, different cytoskeletal proteins, different signalling machin-
ery, and different surface markers (Table 1). The importance of these
differences as they relate to EndMT needs to be fully investigated.
ENDOTHELIAL-TO-MESENCHYMAL TRANSITION
IN DEVELOPMENT
Endothelial-to-mesenchymal transition was first observed in
developmental studies of heart formation (Markwald et al, 1975,
1977). In this context, a subset of endothelial cells lining the
primitive heart tube are triggered to acquire a mesenchymal
phenotype and invade the surrounding tissue, where they
subsequently participate in forming the valves and septa of the
adult heart (Armstrong and Bischoff, 2004). So far, studies of
embryonic heart formation have provided the majority of current
knowledge about EndMT. Mechanistic studies have demonstrated
a role for TGF-b, bone morphogenic protein (BMP), and Notch
pathways (Potts and Runyan, 1989; Nakajima et al, 2000;
Armstrong and Bischoff, 2004; Timmerman et al, 2004; Thiery
and Sleeman, 2006).
ENDOTHELIAL-TO-MESENCHYMAL TRANSITION
IN CANCER AND ANGIOGENESIS
Recently, studies have demonstrated that EndMT can occur in a
variety of pathologic states including cancer (Zeisberg et al, 2007a)
and cardiac fibrosis (Zeisberg et al, 2007b). With regard to cancer,
EndMT is now recognised as a unique source of CAFs (Zeisberg
et al, 2007a). Cancer-associated fibroblasts are known to facilitate
tumour progression in several ways (reviewed by Kalluri and
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Figure 1 Stages of EndMT. (A) Endothelial-to-mesenchymal transition may be initiated by autocrine and/or paracrine inflammatory signals originating
from within the surrounding tissue, such as TGF-b. Possible sources include resident fibroblasts (green) or immune cells (purple). Alternatively, the
endothelium (red) may undergo EndMT in direct response to vascular injury. The vascular basement membrane is likely to be degraded by matrix
metalloproteinases (MMPs) derived from local immune cells. (B–C) Transitioning endothelial cells (red/green) acquire a migratory phenotype, invade under
the vascular basement membrane, and begin to express mesenchymal markers, such as FSP1, while still expressing endothelial markers. (D) Cells that have
undergone EndMT (green) have lost their endothelial phenotype. These EndMT-derived cells contribute to the local fibroblast population and are likely to
produce various growth factors, such as TGF-b. It is not yet known whether the affected vessels are repopulated, and if they remain functional after resident
endothelial cells have departed.
Table 1 Comparison of epithelial, endothelial, and mesenchymal cells
Epithelial cell Endothelial cell Mesenchymal cell
Cell–cell junctions: adherens junctions w/E-cadherin
tight junctions
desmosomes
adherens junctions w/VE-cadherin
limited tight junctions
None (or focal)
Organised cell layer: || No
Apico-basolateral polarity: || No
Basement membrane: || No, but makes interstitial matrix
Migratory: No No |
Intermediate filament: Cytokeratin Vimentin Vimentin
Markers: E-cadherin, claudins, occludins,
desmoplakin, cytokeratin, mucin-1
CD31, VE-cadherin, Tie1, Tie2, VEGFR FSP1, aSMA, vimentin, fibronectin,
vitronectin, collagen types I and III
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discovery of EndMT in tumours was reported in a recent study that
investigated two different mouse models of cancer and demon-
strated that a substantial proportion of CAFs arise through
EndMT. These CAFs were identified as a unique population of
cells that coexpress the endothelial marker CD31 along with one of
the mesenchymal markers, FSP1, or aSMA. Approximately, 40% of
FSP1þ CAFs were also found to be CD31þ, as were 11% of
aSMAþ CAFs. Furthermore, this study also investigated tumours
grown in Tie2-Cre;R26R-lox-STOP-lox-lacZ transgenic mice, a
reporter strain that allows all cells of endothelial origin to be
irreversibly labelled with lacZ expression (Figure 2A). Similar
results were found: among FSP1þ CAFs, 30% were also lacZþ,
and among aSMAþ CAFs, 12% were lacZþ. These data suggest
that EndMT is an important mechanism for CAF recruitment to
the tumour stroma and that these CAFs may have a unique role in
tumour progression. Coincidentally, TGF-b signalling is a known
mediator of EndMT (Nakajima et al, 2000) and is abundantly
expressed in many different tumours (Zeisberg et al, 2007a),
therefore suggesting that EndMT may be mediated by TGF-b
signalling in this context. Nevertheless, the molecular mechanism
of EndMT in tumours has not yet been specifically studied, but is
likely to involve similar pathways as described in the setting of
cardiac fibrosis (Figure 2B).
Taken together, these results demonstrated that up to 40% of
CAFs might be derived through EndMT. This study has
furthermore demonstrated that angiogenic vessels can undergo
EndMT. We speculate that EndMT may play a role in angiogenic
sprouting by enabling the so-called tip cells, which lead an
emerging vascular plexus, to migrate into adjacent tissue. As
migratory cells with no lumen (Gerhardt et al, 2003), tip cells have
a phenotype that appears to be consistent with EndMT. At the
angiogenic front, these migrating endothelial cells are exposed to
growth factors and interstitial matrix molecules, such as type I
collagen, which differ from their normal vascular basement
membrane components (Davis and Senger, 2005). Perhaps in
response to these factors, some endothelial cells may undergo
EndMT and maintain their mesenchymal phenotype indefinitely.
Moreover, previous reports have suggested that vascular support
cells, such as pericytes and/or smooth muscle cells, may arise from
the endothelium itself, and therefore EndMT may be an important
mechanism in recruiting such mural cells during angiogenesis
(Armulik et al, 2005). Furthermore, these vascular support cells
are an important component of mature vessels (Armulik et al,
2005), and therefore EndMT may play an important role in
stabilizing the neovasculature during vasculogenesis and angio-
genesis. This would be consistent with the finding that a
subpopulation of EndMT-derived cells express aSMA, a well-
established marker for pericytes and vascular smooth muscle cells
(Armulik et al, 2005).
ENDOTHELIAL-TO-MESENCHYMAL TRANSITION
IN CARDIAC FIBROSIS AND OTHER
DISEASES
Another recent study has further validated the notion that EndMT
can occur postnatally in the context of disease. This study
addressed EndMT during cardiac fibrosis, a common feature of
most forms of heart failure (Zeisberg et al, 2007b). In fact,
postnatal EndMT has been most extensively studied in this setting
of cardiac fibrosis. Here, approximately 27–35% of all fibroblasts
in fibrotic heart tissue were found to arise through EndMT.
Furthermore, this study demonstrated a role for Smad3-dependent
TGF-b signalling during EndMT in vivo (Figure 2B). Interestingly,
mice treated with recombinant human BMP-7 (rhBMP-7, another
member of the TGF-b superfamily known to antagonise the effects
of TGF-b) exhibited a significant reduction both in fibrosis as well
as EndMT (Figure 2B).
In addition to the studies described above, there is evidence to
suggest that EndMT may occur in many other disease settings,
such as chronic pulmonary hypertension (Zhu et al, 2006;
Arciniegas et al, 2007), atherosclerosis (Mironov et al, 1995),
wound healing (Sarkisov et al, 1988; Lee and Kay, 2006), and in
both acute and chronic kidney injury (Zeisberg et al, 2008). These
emerging reports have characterised EndMT primarily in terms of
marker expression, but have not addressed the precise molecular
mechanisms of EndMT in disease. More importantly, the
functional role of EndMT in each of these scenarios has not yet
been determined.
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Figure 2 Endothelial-to-mesenchymal transition in cancer and cardiac fibrosis. (A) The Tie2-Cre;ROSA-STOP-lacZ reporter mouse is an important strain
for tracking cells of endothelial origin during EndMT. In this mouse, Cre expression is driven by the Tie2 promoter, which is known to be active in endothelial
cells. The Cre recombinase acts by permanently excising genomic DNA regions that are flanked by loxP sites (floxed). In this case, Tie2-driven Cre activity
removes a floxed stop cassette, thereby allowing lacZ expression to be driven by the constitutive ROSA26R promoter (ROSA) without the need for
continued Tie2 activity. (B) During cardiac fibrosis, TGF-b signalling promotes EndMT through Smad3 transcriptional activity. In endothelial cells, TGF-b is
known to activate Alk5, which then activates Smad3. However, the role of Alk5 has not been explicitly demonstrated during EndMT in cardiac fibrosis.
EndMT was also shown to be inhibited by rhBMP-7 (dashed lines). BMP-7 is known to act through a different set of Smads, namely Smad1, -5, and -8. However,
the precise mechanisms whereby BMP-7 inhibits EndMT are not yet known.
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In addition to the in vivo studies described above, a number of
reports have also demonstrated the induction of EndMT in vitro.
To date, many different endothelial cell types, including both
human and mouse, have demonstrated EndMT when exposed to
TGF-b or Notch ligands in vitro (Frid et al, 2002; Ishisaki et al,
2003; Noseda et al, 2004; Timmerman et al, 2004; Zeisberg et al,
2007a,b). These studies have led to a greater understanding of the
mechanisms driving EndMT. In vivo studies have further
substantiated that EndMT can be modulated in response to
manipulations of the TGF-b or Notch pathways (Sanford et al,
1997; Timmerman et al, 2004; Zeisberg et al, 2007b). Still, it is not
clear whether Notch, TGF-b, or a combination of both pathways
provides the initiating signal under physiologic conditions in vivo.
It is also likely that other signalling pathways interact with TGF-b
and Notch to mediate EndMT. For example, VEGF, NFAT, BMP,
Wnt/b-catenin, ErbB, and NF1/Ras have been implicated in
EndMT during cardiac development (Armstrong and Bischoff,
2004), but have yet to be specifically explored in the context of
pathology. In fact, the majority of mechanistic work related to
EndMT has been performed in the context of embryonic
development, and therefore may not reflect the same mechanisms
that occur in disease.
Downstream of these signalling events, the transcriptional
networks mediating EndMT also remain largely unidentified. In
one series of experiments, cells that undergo EndMT exhibited an
increased expression of the Snail family of transcriptional
repressors (Carmona et al, 2000; Romano and Runyan, 2000;
Timmerman et al, 2004). Snail proteins are also known to be
upregulated during EMT, where they play a critical role in
disrupting cell–cell junctions (Batlle et al, 2000; Cano et al, 2000;
Nieto, 2002). In the context of EndMT, Snail repressors are
believed to downregulate VE-cadherin, thereby disrupting adhe-
rens junctions and allowing endothelial cells to delaminate and
undergo EndMT. It is unknown whether other effectors of EMT,
such as Twist (Thiery and Sleeman, 2006), CArG box-binding
factor A (CBF-A), and KRAB-associated protein 1 (KAP-1)
(Venkov et al, 2007), are also involved in EndMT.
PERSPECTIVES AND THERAPEUTIC IMPLICATIONS
Studies of EndMT have revealed a novel mechanism of fibroblast
and mural cell recruitment that is likely to be involved in many
different disease settings. Fibroblasts are known to have an
important role in tissue remodelling and fibrosis (Tomasek et al,
2002; Kalluri and Zeisberg, 2006; Zeisberg et al, 2007a,b), although
previously very little was known about the origin of fibroblasts in
damaged tissues. Various mechanisms have been proposed,
including the activation of local fibroblasts within the affected
tissue, recruitment of bone marrow-derived precursors, and EMT
occurring in nearby epithelia (Iwano et al, 2002). However, in
addition to these mechanisms, it is now clear that EndMT accounts
for a considerable proportion of these fibroblasts, estimated at
27–35% during cardiac fibrosis and up to 40% in tumours
(Zeisberg et al, 2007a,b). This suggests that fibroblasts can be
recruited from a combination of sources, although the relative
contribution from each source may vary in different disease states.
It is also possible that certain vascular beds are more likely to be
affected by EndMT. The endothelium is highly heterogenous and
dynamic by nature, and therefore future studies will need to
address EndMT in the context of this inherent variation in
endothelial phenotypes. For instance, angiogenic vessels in
tumours seem to be particularly prone to EndMT.
Perhaps most importantly, the recent discoveries of EndMT in
different diseases suggest that modulating EndMT may represent a
promising new treatment modality. The endothelium itself is an
attractive target for drug delivery because it lies in direct contact
with the bloodstream. We hypothesise that therapies directed at
inhibiting EndMT may delay tumour progression, perhaps as a
result of impaired angiogenesis or CAF recruitment. Possible
treatment strategies may target the TGF-b and/or BMP signalling
pathways. The mouse studies described above have demonstrated
that systemic administration of rhBMP-7 significantly reduced
EndMT during cardiac fibrosis (Zeisberg et al, 2007b). Follow-up
studies should be pursued to address possible effects of BMP-7
treatment on EndMT in tumours and to identify other EndMT
targets.
Furthermore, inhibiting EndMT may be broadly applicable to
various disease states. For example, preventing EndMT during
chronic organ fibrosis may significantly delay disease progression
and allow patients to maintain adequate organ function for a
longer period of time. Nevertheless, additional studies are needed
to identify the precise molecular mechanisms of EndMT in disease
and to determine which signalling components might be viable
therapeutic targets. A promising place to start may be to further
examine the developmental defects in EndMT. Just as normal
developmental mechanisms are often recapitulated in certain
disease states (Reya et al, 2001), the corresponding developmental
defects might provide unique insights into possible treatments for
those diseases. In conclusion, the study of EndMT represents an
exciting new frontier in vascular biology that will continue to
provide novel insights into the mechanisms of human disease.
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